R&D News | pharmaphorum

News

Roche’s MS drug Ocrevus earns blockbuster status a year afte...

Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched.

News

Merck & Co's Keytruda shows potential in head and neck cance...

Merck & Co might be able to find another use for its immunotherapy Keytruda in first line head and neck cancer, after revealing promising phase 3 trial results.

News

GSK's Nucala unlikely to get COPD use after panel vote

FDA due to make decision in September

News

Closeup of X-ray photography of human brain

Biogen and Eisai Alzheimer's drug excites doctors, but not i...

Investors spooked after string of failures

R&D

GSK signs $300m R&D deal with 23andMe

GlaxoSmithKline signed a $300 million research and development deal with mail gene profiling company 23andMe, gaining access to four million customers DNA information.

News